^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AMLM26/T1 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics - Gilteritinib+ Venetoclax
Excerpt:
...To determine the MRD response of patients with FLT3-mutated AML in the MRD failure stratum to their first exposure to decision rule guided therapy with Venetoclax and Gilteritinib. ...
Trial ID:
Source:
Title:
Preclinical Assessment of Dual FLT3 and BCL 2 Inhibition in Lineage Ambiguous Leukemia
Published date:
09/01/2023
Excerpt:
We performed preclinical drug testing of the BCL-2 inhibitor, venetoclax, and the FLT3 inhibitor, gilteritinib, in two FLT3-mutant BCL11B-a PDX models: one T/myeloid MPAL and one acute undifferentiated leukemia (AUL)…Single agent gilteritinib showed increased efficacy compared with venetoclax; however, gilteritinib was unable to prevent continued leukemic growth over the 8-week treatment. In contrast, combination therapy rapidly and stably reduced leukemic burden to pre-treatment levels....We showed that the combination of FLT3 and BCL-2 inhibition is highly effective at reducing leukemia burden in two preclinical models of BCL11B-a lineage ambiguous leukemia.
